secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001736730-25-000072
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

CAMP4 Therapeutics announces up to $100M private placement and board changes
----------------------------------------------------------------------------

- Initial closing raises $50M from 26.7M shares at $1.53/share, pre-funded warrants, and management shares; total upfront proceeds ~$50M.
- Second closing of up to $50M contingent on regulatory clearance for SYNGAP1 trial and stock price milestone or waiver.
- Directors James Boylan, Ravi Thadhani, and Paula Ragan resigned; Doug Williams appointed Board Chair.
- Daniel Tardiff elevated to Chief Scientific Officer effective October 1, 2025.
- Financing led by Coastlands Capital with Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures and others.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/0001736730-25-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/camp-20250909.htm
  HTML page:      https://secwatch.observer/filing/0001736730-25-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer